Merck & Co Inc (MRK)
98.50
-0.08
(-0.08%)
USD |
NYSE |
Nov 13, 16:00
98.69
+0.19
(+0.19%)
After-Hours: 20:00
Merck Research and Development Expense (Quarterly): 5.862B for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
Date | Value |
---|---|
September 30, 2024 | 5.862B |
June 30, 2024 | 3.50B |
March 31, 2024 | 3.992B |
December 31, 2023 | 9.627B |
September 30, 2023 | 3.307B |
June 30, 2023 | 13.32B |
March 31, 2023 | 4.276B |
December 31, 2022 | 3.775B |
September 30, 2022 | 4.399B |
June 30, 2022 | 2.798B |
March 31, 2022 | 2.576B |
December 31, 2021 | 3.068B |
September 30, 2021 | 2.445B |
June 30, 2021 | 4.321B |
March 31, 2021 | 2.412B |
December 31, 2020 | 5.788B |
September 30, 2020 | 3.349B |
June 30, 2020 | 2.085B |
March 31, 2020 | 2.209B |
December 31, 2019 | 2.40B |
September 30, 2019 | 3.204B |
June 30, 2019 | 2.189B |
March 31, 2019 | 1.931B |
December 31, 2018 | 2.214B |
September 30, 2018 | 2.068B |
Date | Value |
---|---|
June 30, 2018 | 2.274B |
March 31, 2018 | 3.196B |
December 31, 2017 | 2.315B |
September 30, 2017 | 4.413B |
June 30, 2017 | 1.782B |
March 31, 2017 | 1.83B |
December 31, 2016 | 4.786B |
September 30, 2016 | 1.664B |
June 30, 2016 | 2.151B |
March 31, 2016 | 1.659B |
December 31, 2015 | 1.798B |
September 30, 2015 | 1.50B |
June 30, 2015 | 1.67B |
March 31, 2015 | 1.737B |
December 31, 2014 | 2.283B |
September 30, 2014 | 1.659B |
June 30, 2014 | 1.664B |
March 31, 2014 | 1.574B |
December 31, 2013 | 1.835B |
September 30, 2013 | 1.66B |
June 30, 2013 | 2.101B |
March 31, 2013 | 1.907B |
December 31, 2012 | 2.224B |
September 30, 2012 | 1.918B |
June 30, 2012 | 2.165B |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
2.085B
Minimum
Jun 2020
13.32B
Maximum
Jun 2023
4.276B
Average
3.424B
Median
Research and Development Expense (Quarterly) Benchmarks
Amgen Inc | 1.45B |
Johnson & Johnson | 4.952B |
Eli Lilly and Co | 2.734B |
Pfizer Inc | 2.598B |
AbbVie Inc | 2.13B |